OKYO Pharma Limited (OK10.F)
- Previous Close
1.3600 - Open
1.3600 - Bid --
- Ask --
- Day's Range
1.3600 - 1.3600 - 52 Week Range
1.1000 - 1.6900 - Volume
1,192 - Avg. Volume
0 - Market Cap (intraday)
38.379M - Beta (5Y Monthly) -2.91
- PE Ratio (TTM)
-- - EPS (TTM)
-0.5600 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.
www.okyopharma.comRecent News: OK10.F
Performance Overview: OK10.F
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: OK10.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: OK10.F
Valuation Measures
Market Cap
45.55M
Enterprise Value
43.84M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-3.33
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-173.43%
Return on Equity (ttm)
-2,968.51%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-13.27M
Diluted EPS (ttm)
-0.5600
Balance Sheet and Cash Flow
Total Cash (mrq)
4.05M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-2.77M
Company Insights: OK10.F
OK10.F does not have Company Insights